TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03658850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 50Mg
Description: for the experimental group received a hydrochlorothiazide tablet on presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally on day 0 (D0) until day 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3
Study: NCT00202644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide
Description: Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
Study: NCT04212247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-Being Therapy
Description: Well-Being Therapy (WBT) is a short-term psychotherapeutic strategy, that emphasizes self-observation with the use of a structured diary, interaction between patients and therapists and homework. WBT was based on the model of psychological well-being that was originally developed by Jahoda in 1958 and further refined by Ryff in 2014. The standard number of sessions is 8. The initial phase is concerned with self-observation of psychological well-being. Then, the patient is encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of wellbeing. The final part involves cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control condition
Description: The control condition will include 8 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drug misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
Study: NCT01356745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premixed 50% nitrous oxide and oxygen (Kalinox)
Description: 15 min inhalation dose (maximum duration of treatment of a subject)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: medical air
Description: inhalation gas for inhalation use
Study: NCT04275440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: 1. In the first two weeks, participants would reduce their daily energy intake to 100% -110% of his or her basal metabolic energy under instruction, and stick to it till the end of the intervention.~2. According to the dietary recommendation proposed by Chinese government, participants are required to take in cereals, vegetables, fruits, meat and eggs, while minimize the consumption of sugar-sweeten beverages.~3. Participants are instructed to arrange their three meals according to the recommended energy distribution (3:4:3).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: 1. In the first two weeks, participants would reduce their daily energy intake to 100% -110% of his or her basal metabolic energy under instruction, and stick to it till the end of the intervention.~2. According to the dietary recommendation proposed by Chinese government, participants are required to take in cereals, vegetables, fruits, meat and eggs, while minimize the consumption of sugar-sweeten beverages.~3. Participants are instructed to arrange their three meals according to the recommended energy distribution (3:4:3).
Study: NCT03878745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Terumo Nanopass® 34G pen needle
Description: Insulin pen needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Terumo Nanopass® 34G pen needle
Description: Insulin pen needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD Nano™ PRO 32G pen needle
Description: Insulin pen needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BD Nano™ PRO 32G pen needle
Description: Insulin pen needle
Study: NCT04015245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stronger Neo-Minophagen C
Description: intravenous injection after TACE
Study: NCT04645641

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring System
Description: Continuous Glucose Monitoring System
Study: NCT04063956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi-domain internet-based adaptive training program
Description: The training paradigms include a time perception task, visual search task, rapid serial presentation task, delayed match to sample task, paired-associate recall task, attention span task, digit span task, go-no go task, Stroop task, task switching, auditory span task and n-back working memory task. Each task has several difficulty levels. The tasks are grouped in different cognitive domains including: processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning, and problem-solving. Participants in the cognitive training group will complete 40 min of training daily, 4 days a week for 12 weeks. When a high accuracy (80%) is achieved for each task, the level of difficulty will be upgraded for that task.
Study: NCT01199640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
Study: NCT05753124

Intervention type: OTHER
Intervention: Observational
Description: This is an observational study
Study: NCT02417935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT00392210

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Voiding Trial
Description: Post-void residual and uroflow study will be done twice
Study: NCT02683135

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-carbohydrate diet
Description: Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Description: Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Description: Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet with post-meal walking
Description: Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning \~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
Study: NCT04651751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitating an Exercise Habit and Identity via the Multi-Process Action Control Model- A Randomized-Controlled Trial
Description: Participants attended a workshop which consisted of a presentation and an exercise planning exercise.
Study: NCT01277666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786A
Description: 500 mg twice daily, administered orally for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786A
Description: 500 mg once daily, administered orally for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, administered orally for 12 weeks
Study: NCT01948089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable Structured Cognitive Exercise
Description: This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will vary weekly, and include varying auditory letters or words, or varying visual patterns or faces.
Study: NCT04214626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Study: NCT04063956

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active-control program
Description: For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
Study: NCT01948089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constant Structured Cognitive Exercise
Description: This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will remain constant throughout the 10 week intervention
Study: NCT05071391

Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass
Description: Gastric bypass, also called Roux-en-Y gastric bypass, is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine. After gastric bypass, swallowed food will go into this small pouch of stomach and then directly into the small intestine, thereby bypassing most of your stomach and the first section of your small intestine.~Gastric bypass is one of the most commonly performed types of bariatric surgery. Gastric bypass is done when diet and exercise haven't worked or when you have serious health problems because of your weight.
Study: NCT02993289

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different well-known treatments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different well-known treatments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different well-known treatments
Study: NCT05383300

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin nasal spray
Description: Intranasal spray containing 40 IU of oxytocin
Study: NCT04214626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Induction Chemotherapy: 1g/m2, Intravenous administration on day 3 of each 3-week cycle from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.
Study: NCT01551381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV-077
Description: twice daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily oral administration
Study: NCT00808028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal B rLP2086 vaccine.
Description: vaccine, 0.5 mL, 0 - 2 - 6 to 9 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal B rLP2086 vaccine.
Description: vaccine, 0.5 mL, 0 - 2 - 6 to 9 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal B rLP2086 vaccine.
Description: vaccine, 0.5 mL, 0 - 2 - 6 to 9 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline (placebo)
Description: vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
Study: NCT00098865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: The lower 150/m2 Temozolomide dose was for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal raditation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Calculated dose was rounded down to the nearest 50mg, or up to 50mg if calculated dose was less than 50mg. Patients increased the daily dose by 50mg (one capsule) on a weekly basis unitl either unacceptable toxicity or a maximum dose.
Study: NCT04302363

Intervention type: OTHER
Intervention: Fecal microbiota detection and exfoliated cell gene detection
Description: Fecal microbiota detection and exfoliated cell gene detection

Intervention type: OTHER
Intervention: Fecal microbiota detection and exfoliated cell gene detection
Description: Fecal microbiota detection and exfoliated cell gene detection
Study: NCT02884440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP block ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAP block placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: General anesthesia
Description: Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary DEXAMETHASONE 8 mg KETAMINE 0,15mg/kg Maintenance PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary DEXAMETHASONE 8 mg KETAMINE 0,15mg/kg Maintenance PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml
Study: NCT00643851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablets, Oral, Once daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Tablets, Oral, Once daily, 24 weeks
Study: NCT02655211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser treatment
Description: Surgical treatment using fractionated ablative carbon dioxide laser (CO2)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser treatment
Description: Surgical treatment using fractionated ablative carbon dioxide laser (CO2)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser treatment
Description: Surgical treatment using fractionated ablative carbon dioxide laser (CO2)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser treatment
Description: Surgical treatment using fractionated ablative carbon dioxide laser (CO2)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser treatment
Description: Surgical treatment using fractionated ablative carbon dioxide laser (CO2)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser treatment
Description: Surgical treatment using fractionated ablative carbon dioxide laser (CO2)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser treatment
Description: Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
Study: NCT05383300

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin nasal spray
Description: Intranasal spray containing 40 IU of oxytocin

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin nasal spray
Description: Intranasal spray containing 40 IU of oxytocin

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo spray
Description: Application of inert placebo, identical in odor, color, and droplet size except for absence of oxytocin
Study: NCT05327231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
Study: NCT05383300

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo spray
Description: Application of inert placebo, identical in odor, color, and droplet size except for absence of oxytocin

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo spray
Description: Application of inert placebo, identical in odor, color, and droplet size except for absence of oxytocin
Study: NCT01475331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: Cysts will be lavaged for 3-5 minutes with 80% EtOH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Cysts will be lavaged for 3-5 minutes with normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
Study: NCT02655211

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
Study: NCT01833299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE-Sorafenib group
Description: Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.~Oral sorafenib (400 mg BID) will be start the 2-4 weeks after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE